Personalis (NASDAQ:PSNL) Trading 5.8% Higher – What’s Next?

Personalis, Inc. (NASDAQ:PSNL) traded up 5.8% during mid-day trading on Tuesday . The company traded as high as $10.35 and last traded at $10.3540. 707,709 shares were traded during trading, a decline of 63% from the average session volume of 1,908,138 shares. The stock had previously closed at $9.79.

Analyst Upgrades and Downgrades

A number of research firms recently weighed in on PSNL. Wall Street Zen cut Personalis from a “hold” rating to a “sell” rating in a report on Saturday. Needham & Company LLC lifted their price target on Personalis from $10.00 to $12.00 and gave the company a “buy” rating in a report on Friday, February 27th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Personalis in a research report on Tuesday, April 21st. BTIG Research lowered their price objective on Personalis from $13.00 to $11.00 and set a “buy” rating for the company in a research report on Monday, May 11th. Finally, Morgan Stanley lowered their price objective on Personalis from $10.00 to $9.00 and set an “equal weight” rating for the company in a research report on Tuesday, May 12th. Five investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, Personalis currently has an average rating of “Moderate Buy” and an average target price of $11.00.

Personalis Stock Performance

The company has a market capitalization of $1.06 billion, a price-to-earnings ratio of -9.96 and a beta of 2.27. The company has a 50-day moving average price of $7.61 and a 200-day moving average price of $8.24.

Personalis (NASDAQ:PSNL) last posted its earnings results on Thursday, May 7th. The company reported ($0.29) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.23) by ($0.06). The company had revenue of $15.47 million for the quarter, compared to analyst estimates of $14.49 million. Personalis had a negative return on equity of 43.52% and a negative net margin of 148.11%. As a group, sell-side analysts anticipate that Personalis, Inc. will post -1.06 earnings per share for the current fiscal year.

Insider Activity at Personalis

In related news, CEO Christopher M. Hall sold 80,091 shares of the business’s stock in a transaction that occurred on Friday, May 29th. The stock was sold at an average price of $11.02, for a total value of $882,602.82. Following the completion of the transaction, the chief executive officer directly owned 235,986 shares in the company, valued at approximately $2,600,565.72. The trade was a 25.34% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Aaron Tachibana sold 40,000 shares of the business’s stock in a transaction dated Thursday, June 4th. The shares were sold at an average price of $12.01, for a total value of $480,400.00. Following the completion of the sale, the chief financial officer owned 198,833 shares in the company, valued at approximately $2,387,984.33. This trade represents a 16.75% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 178,799 shares of company stock valued at $2,031,692 over the last quarter. 4.20% of the stock is owned by insiders.

Hedge Funds Weigh In On Personalis

A number of large investors have recently bought and sold shares of PSNL. Caitong International Asset Management Co. Ltd boosted its position in Personalis by 76.1% during the 4th quarter. Caitong International Asset Management Co. Ltd now owns 3,423 shares of the company’s stock worth $27,000 after acquiring an additional 1,479 shares during the last quarter. Legal & General Group Plc acquired a new stake in shares of Personalis in the 2nd quarter valued at approximately $30,000. International Assets Investment Management LLC acquired a new stake in shares of Personalis in the 4th quarter valued at approximately $31,000. BNP Paribas Financial Markets boosted its holdings in shares of Personalis by 406.4% in the 2nd quarter. BNP Paribas Financial Markets now owns 6,451 shares of the company’s stock valued at $42,000 after buying an additional 5,177 shares during the last quarter. Finally, Focus Partners Wealth acquired a new position in Personalis during the first quarter worth approximately $47,000. Institutional investors and hedge funds own 61.91% of the company’s stock.

About Personalis

Personalis, Inc (NASDAQ: PSNL) is a clinical‐stage genomics company that develops and markets advanced next‐generation sequencing (NGS) services and assays designed to accelerate precision medicine. The Company’s core offering is the ImmunoID NeXT™ Platform, which combines comprehensive tumor profiling—including whole exome, transcriptome, and T‐cell receptor sequencing—with proprietary bioinformatics to identify biomarkers and guide immuno‐oncology research. Personalis serves biopharmaceutical companies, academic institutions, and clinical research organizations seeking in‐depth insights into cancer, autoimmune diseases and other complex conditions.

In addition to its flagship ImmunoID NeXT™ Platform, Personalis offers a suite of customizable sequencing assays for biomarker discovery, clinical trial support and companion diagnostic development.